Alzheimer's biotech Alzheon nets $50M Series D; Evelo puts PhI atopic dermatitis program on hold
A Framingham, MA-based biotech has some new cash to play with.
Alzheon announced Thursday morning it has completed a $50 million Series D round aimed to advance a Phase III study for its oral Alzheimer’s program, as well as to help prep the drug’s regulatory filings. The candidate, dubbed ALZ-801, is an oral tablet being evaluated for patients with early-stage Alzheimer’s disease.
“[The] Series D financing and recent validating data will accelerate development of ALZ-801 to potentially become the first oral agent that can slow or even stop and prevent Alzheimer’s pathology in all patients and healthy individuals at risk for the disease,” CEO Martin Tolar said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.